Cost-effectiveness of Direct Oral Anticoagulant vs. Warfarin Among Atrial Fibrillation Patients With Intermediate Stroke Risk

BACKGROUND: Several studies have shown the cost-effectiveness of direct oral anticoagulants (DOACs), compared with warfarin, to prevent atrial fibrillation (AF) related complications. However, few have reported cost-effectiveness of DOACs in AF patients with intermediate stroke risk. Thus, we invest...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Ju Hee, Kim, Woojin, Kim, Yun Tae, Cho, Jaelim, Shin, Seung Yong, Kim, Changsoo, Kim, Jin-Bae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035745/
https://www.ncbi.nlm.nih.gov/pubmed/35479283
http://dx.doi.org/10.3389/fcvm.2022.849474

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035745/
https://www.ncbi.nlm.nih.gov/pubmed/35479283
http://dx.doi.org/10.3389/fcvm.2022.849474

Ejemplares similares